Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

By M. Arbyn, G. Ronco, A. Anttila, C. Meijer, M. Poljak, G. Ogilvie, G. Koliopoulos, P. Nauclér, R. Sankaranarayanan, J. Peto. Vaccine, 2012

885 citations recorded by the source corpus.

Subfields: Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/1b82907503d0a2b55dad286722a982c8b57405dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Moscicki
2. Mark Schiffman
3. M. Arbyn
4. M. Stanley

In Surgery

1. A. Moscicki
2. Mark Schiffman
3. M. Stanley

Citations in the corpus

• Metaprop: a Stata command to perform meta-analysis of binomial data (2014, methodology): “HPV testing has been proposed as a method to triage women with minor cytological abnormalities identified through screening for cervical cancer using the Pap smear [19,20].”
• 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors (2020, methodology): “Rationale: The preferential use of HPV-based testing (cotesting or HPV primary testing) is supported by evidence that posttreatment HPV testing is the most accurate predictor of treatment outcome.(125) Although the relative risk of persistent or recurrent histologic HSIL (CIN 2+) is almost 5 times h”